Peptides Similar to Insulin

Peptides Related to Insulin#

Several peptides share functional overlap with Insulin in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

Objective: Provide a comparative assessment of research efficacy for insulin versus TB-500/Thymosin β4 and GHK-Cu across overlapping indications, emphasizing randomized/controlled human studies, quantitative outcomes, safety, and head-to-head evidence.

Summary of findings

• Overall evidence strength: Insulin has the most consistent randomized/controlled human evidence for wound healing (cutaneous and corneal), including a meta-analysis of clinical studies. Thymosin β4 (including topical RGN‑137 and ophthalmic RGN‑259) has Phase 2 randomized trials with mixed efficacy signals (generally acceptable safety). GHK‑Cu has small cosmetic RCTs suggesting anti-wrinkle effects, but limited rigorous wound-healing RCTs in humans. No head-to-head RCTs directly comparing insulin with Tβ4 or GHK‑Cu were identified.

Cutaneous wound healing

• Insulin: A meta-analysis pooling four clinical and nine animal studies reported substantial improvements with topical insulin. In clinical studies, wound healing time decreased markedly (SMD −2.48, 95% CI −3.44 to −1.51) and wound healing rate increased (22.23, 95% CI 18.17–26.28) versus controls, supporting a clinically meaningful acceleration of healing; safety reporting was limited in the meta-analysis but topical use is generally well tolerated in RCTs (see corneal data).
• Thymosin β4 (TB‑500/Tβ4): In a Phase 2 randomized, double‑blind, placebo‑controlled topical gel trial in chronic venous/pressure ulcers (N≈72), the 0.03% dose achieved complete healing in 33.3% vs 23.5% with placebo by Day 84; other doses were 15.8–16.7%. Too few ulcers healed to estimate median time; safety was acceptable with no drug-related serious adverse events (crockford2010thymosinβ4structure pages 4-6, crockford2010thymosinβ4structure pages 2-4). These results suggest possible benefit at one dose level but overall modest and dose‑inconsistent efficacy compared with insulin’s pooled effects.
• GHK‑Cu: Human RCT evidence for wound healing is sparse. Reviews cite largely preclinical data and small clinical observations; robust, large RCTs in wound indications were not identified in the gathered evidence.

Corneal epithelial healing

• Insulin: A randomized, double‑blind controlled trial of topical insulin drops after vitreoretinal surgery in diabetics (32 eyes; 8 per arm) found the 0.5‑unit dose achieved 100% healing within 72 hours versus 62.5% with placebo, with a significantly faster mean healing rate (P=0.036). No ocular adverse effects or systemic absorption were reported.
• Thymosin β4: Ophthalmic RGN‑259 has Phase 2 randomized, placebo‑controlled data in a controlled adverse environment (CAE) dry‑eye model (N=72). Primary endpoints were not met; several secondary endpoints improved significantly (e.g., ~27% symptom reduction and improved corneal staining), and safety was favorable. Compassionate-use and small series in corneal epithelial disease suggest potential benefit, but randomized evidence in corneal epithelial defects is limited relative to insulin.
• GHK‑Cu: No corneal RCT evidence was identified.

Dry eye signs/symptoms

• Insulin: No randomized dry‑eye trials were identified in the gathered corpus.
• Thymosin β4: In the Phase 2 CAE trial, primary endpoints were not met, but statistically significant improvements in several secondary signs/symptoms were observed; safety was acceptable.
• GHK‑Cu: Not established for dry eye in clinical trials.

Cosmetic skin outcomes (wrinkles)

• GHK‑Cu: Small randomized, placebo‑controlled cosmetic trials report reduced wrinkle volume and depth (e.g., ~31.6% reduction vs Matrixyl 3000; ~55.8% vs control in one study) and improvements in skin parameters, though detailed sample sizes and standardized endpoints vary and adverse event reporting is limited.
• Insulin and Thymosin β4: Cosmetic anti‑wrinkle RCT data were not identified in the gathered evidence; both have been studied primarily for tissue repair and wound indications.

Safety overview

• Insulin: Topical application in corneal RCT showed no ocular adverse events and no systemic absorption; mechanistic RCT in cutaneous ulcers reported clinical benefit with topical use, though dosing must avoid systemic glycemic effects in preclinical models.
• Thymosin β4: Across Phase 2 skin/ulcer and ophthalmic trials, safety/tolerability were generally acceptable, with no drug‑related serious adverse events reported and mostly mild adverse events comparable to placebo.
• GHK‑Cu: Long history of cosmetic use with generally favorable tolerability; formal adverse‑event reporting in controlled trials is limited.

Head‑to‑head evidence

• No randomized controlled head‑to‑head trials comparing insulin directly with Thymosin β4 (TB‑500) or GHK‑Cu were identified. Evidence is derived from separate trials and meta‑analyses, limiting direct comparative inference.

Clinical interpretation

• For wound‑healing indications, the weight of randomized/controlled human evidence favors topical/local insulin, with both corneal and cutaneous data showing clinically meaningful benefits and acceptable safety. Thymosin β4 shows signals of benefit in selected contexts but with mixed or dose‑inconsistent efficacy in Phase 2 ulcer trials and non‑significant primary endpoints in a dry‑eye Phase 2 trial; safety is acceptable. GHK‑Cu has suggestive cosmetic RCT data for wrinkles but lacks robust wound‑healing RCTs; thus, its evidence base for clinical wound repair is weaker than insulin’s and at most comparable to exploratory signals for Tβ4 in non‑wound cosmetic contexts.

Embedded summary table

Limitations

• Extracted quantitative details for some trials (e.g., full outcome tables, adverse event frequencies) were limited in the available excerpts. Nevertheless, the direction and magnitude of the key outcomes are consistent across sources. No head‑to‑head trials were found, so cross‑agent comparisons are indirect and should be interpreted accordingly.

LL-37 (Cathelicidin)#

• Evidence directly combining insulin with a healing peptide/growth factor in humans exists (rh‑bFGF + local insulin in randomized diabetic burn patients), but quantitative outcomes were not available in the provided excerpt. This supports feasibility and suggests benefit, though effect size and safety details require retrieval of the primary report.
• Robust preclinical synergy is demonstrated for IGF‑1 (same signaling superfamily as insulin) with substance P–derived peptides in multiple corneal models, including diabetic settings, with consistent mechanistic readouts (integrins/FAK/paxillin) and superior wound closure versus monotherapy.
• Classic skin wound data show PDGF + IGF‑I synergy on dermal/epidermal repair in swine, reinforcing that co‑targeting the IGF/insulin axis with other growth factors can yield supra‑additive effects.
• Collectively, these lines of evidence support a biologically plausible and, in limited cases, clinically tested complementary or synergistic effect when insulin is combined with healing peptides/growth factors. Direct, modern RCT data of insulin co‑administered with specific peptides (e.g., LL‑37, thymosin β4) in human cutaneous wounds were not identified in the retrieved registry results or excerpts; this remains a gap.

Key gaps and future directions

• Quantify clinical benefit: Accessing the primary randomized burn study (rh‑bFGF + insulin) is necessary to extract healing rates, time‑to‑closure, and adverse events. Additional controlled trials in chronic diabetic foot ulcers or complex wounds testing insulin + EGF/FGF/PDGF/host defense peptides would clarify effect sizes and generalizability.
• Extend to antimicrobial peptides: While host defense peptides such as LL‑37 show wound‑healing and immunomodulatory activity, direct combination studies with insulin were not found in the provided evidence set. Given insulin’s pro‑angiogenic and pro‑migration effects, complementary benefits with antimicrobial/immune‑active peptides are plausible and merit investigation.

Mechanism Comparison#

IGF-1 and IGF-2: IGF-1 primarily activates IGF-1R (RTK) and can signal through IR/IGF-1R hybrids; at high concentrations it can activate IR. IGF-2 activates IGF-1R and, crucially, binds IR-A with meaningful affinity, as well as hybrid receptors. Downstream signaling is highly overlapping with insulin—receptor autophosphorylation leading to IRS/Shc recruitment, PI3K–AKT, and Ras–MAPK activation—though physiological roles skew toward growth, survival, and differentiation rather than acute metabolic control. In cancer, an IGF-2–IR-A autocrine loop is recognized.

Insulin analogs: Clinically used analogs engage IR-A/IR-B with kinetic and affinity differences; some show increased IGF-1R or IR-A engagement and prolonged receptor residence, which can shift mitogenic tone despite preserving metabolic signaling via IRS–PI3K–AKT. Thus, analogs share insulin’s mechanism but differ quantitatively in receptor targeting and downstream output.

Relaxin/insulin-like peptides (RLN1–3, INSL3, INSL5): Despite structural homology to insulin, these ligands act at RXFP1–4 GPCRs, not RTKs. RXFP1/2 (LRR-GPCRs) predominantly raise cAMP via Gs with additional Gi3/Gβγ inputs and can activate ERK; RXFP3/4 are Gi/o-coupled, inhibit cAMP, and activate ERK and PI3K–AKT–mTOR cascades via Src and β-arrestins. INSL5 at RXFP4 exemplifies GPCR-driven activation of ERK and PI3K–Akt (mTORC2-dependent) while inhibiting cAMP. Thus, receptor class and proximal mechanism differ, but there is distal convergence on ERK and PI3K–AKT modules.

Incretins (GLP-1, GIP): GLP-1 and GIP signal via class B GPCRs (GLP-1R, GIPR) that couple to Gs to increase cAMP and activate PKA and Epac, with additional coupling to PLC/PKC and Ca2+ pathways in beta cells. These pathways potentiate glucose-dependent insulin secretion. Although they do not engage RTKs or IRS adaptors, their downstream signaling can interface with PI3K/ERK networks in some contexts; overlap with insulin lies mainly in functional integration at the level of metabolic control rather than shared receptor mechanisms.

Which peptides share overlapping mechanisms with insulin?

• Strong, direct overlap (shared receptor class and proximal adaptors): IGF-1 and IGF-2. Both use RTKs (IGF-1R and IR/IGF-1R hybrids) and recruit IRS/Shc to activate PI3K–AKT and Ras–MAPK, and IGF-2 can signal via IR-A itself.
• Full mechanistic overlap by design: Insulin analogs, with caveats about altered IR isoform/IGF-1R engagement and kinetics that can bias signaling.
• Partial, distal overlap (distinct receptors but convergence on ERK and/or PI3K–AKT effectors): Relaxin family peptides (RXFP1–4) and INSL5/RXFP4; they are GPCR-driven but activate ERK and PI3K–Akt–mTOR modules downstream.
• Functional, not mechanistic, overlap: Incretins GLP-1/GIP, which enhance insulin secretion via GPCR–cAMP–PKA/Epac pathways; they can intersect with broader kinase networks but do not share IR/IGF1R–IRS proximal mechanisms.

Concise comparison

In summary, insulin, IGF-1, and IGF-2 comprise a mechanistic cluster centered on RTK receptors (IR isoforms, IGF-1R, and hybrids) and shared IRS/Shc-driven PI3K–AKT and Ras–MAPK signaling. Relaxin-family peptides and incretins act via GPCRs, showing only distal convergence on ERK and PI3K–AKT, and thus do not share insulin’s primary receptor mechanism.

Combination and Synergy#

Summary of combination evidence

• Clinical signal for insulin + growth factor combinations in cutaneous wounds: A systematic review of topical biologics for diabetic wounds cites a randomized human study in diabetic deep second-degree burns where recombinant human basic fibroblast growth factor (rh‑bFGF) was combined with local insulin (along with polymyxin B ointment), reporting improved wound healing with the combination versus control. The excerpted source lists the study but does not provide effect sizes; it establishes that such clinical combination regimens have been investigated (randomized design).

• Strong adjacent synergy in the insulin/IGF axis with peptides in ocular wound healing: • IGF‑1 + substance P (or its minimal C‑terminal peptide FGLM‑NH2) synergistically accelerates corneal epithelial migration and wound closure in rabbit models; neither component alone was effective. Mechanistically, the combination increases epithelial attachment to fibronectin, upregulates α5β1 integrins, and promotes focal adhesion signaling, consistent with true synergy on cell migration/adhesion rather than proliferation (no increase in [3H]‑thymidine incorporation). • In streptozotocin‑diabetic rats with corneal epithelial debridement, topical FGLM‑NH2 + IGF‑1 markedly increased the rate of wound closure versus diabetic vehicle, approaching non‑diabetic healing rates; the combo also increased integrin α5 and phosphorylation of paxillin/FAK. This provides disease‑context synergy supportive of translational relevance.

• Growth factor synergy in skin that informs insulin‑axis combinations: In partial‑thickness porcine skin wounds, PDGF‑BB (PDGF‑2) combined with IGF‑I produced a marked increase in connective tissue volume, collagen content/maturity, and normal epithelial differentiation, while either agent alone had limited effect; an optimal PDGF:IGF ratio of ~2:1 by weight was described. This foundational in vivo study demonstrates greater‑than‑additive effects within the insulin/IGF axis on cutaneous repair.

• Complementarity rationale specific to insulin: Topical insulin monotherapy accelerates healing and activates pathways that can complement peptide/growth factor actions. Clinical and translational data show insulin enhances AKT and ERK signaling, upregulates VEGF/eNOS/SDF‑1α, and promotes keratinocyte migration and angiogenesis, shortening time‑to‑heal in randomized and meta‑analytic assessments. These mechanisms are complementary to peptides that primarily enhance migration/ECM engagement (e.g., EGF/FGF/PDGF, host defense peptides), supporting plausibility for combination benefit even when direct synergy data are sparse.

Combination study data and models at a glance

Evidence Gaps#

Direct head-to-head comparison studies between Insulin and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• Insulin overview and research guide
• Insulin research evidence
• Insulin dosing protocols